References
- SEER Stat Fact Sheets: Melanoma of the Skin. [cited 2016 Mar 31]. Available from: http://seer.cancer.gov/statistics/summaries.html
- Balch CM, Gershenwald JE, Soong S-J, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27(36):6199–6206.
- Garbe C, Eigentler TK, Keilholz U, et al. Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist. 2011;16(1):5–24.
- Liu Y, Sheikh MS. Melanoma: molecular pathogenesis and therapeutic management. Mol Cell Pharmacol. 2014;6(3):228.
- Akinleye A, Furqan M, Mukhi N, et al. MEK and the inhibitors: from bench to bedside. J Hematol Oncol. 2013;6:27.
- Ribas A, Gonzalez R, Pavlick A, et al. Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study. Lancet Oncol. 2014;15(9):954–965.
- Falchook GS, Long GV, Kurzrock R, et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet. 2012;379(9829):1893–1901.
- Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. New England J Med. 2011;364(26):2507–2516.
- Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380(9839):358–365.
- Larkin J, Ascierto PA, Dreno B, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014;371(20):1867–1876.
- Long GV, Stroyakovskiy D, Gogas H, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med. 2014;371(20):1877–1888.
- Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372(1):30–39.
- Shain AH, Yeh I, Kovalyshyn I, et al. The genetic evolution of melanoma from precursor lesions. N Engl J Med. 2015;373(20):1926–1936.
- Cancer Genome Atlas Network. Genomic classification of cutaneous melanoma. Cell. 2015;161(7):1681–1696.
- Whittaker SR, Theurillat JP, Van Allen E, et al. A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. Cancer Discov. 2013;3(3):350–362.
- Garnett MJ, Rana S, Paterson H, et al. Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization. Mol Cell. 2005;20(6):963–969.
- Terai K, Matsuda M. The amino-terminal B-Raf-specific region mediates calcium-dependent homo- and hetero-dimerization of Raf. Embo J. 2006;25(15):3556–3564.
- Shi H, Hong A, Kong X, et al. A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition. Cancer Discov. 2014;4(1):69–79.
- Trunzer K, Pavlick AC, Schuchter L, et al. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol. 2013;31(14):1767–1774.
- Shi H, Moriceau G, Kong X, et al. Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun. 2012;3:724.
- Poulikakos PI, Persaud Y, Janakiraman M, et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature. 2011;480(7377):387–390.
- Nazarian R, Shi H, Wang Q, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010;468(7326):973–977.
- Wilson TR, Fridlyand J, Yan Y, et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature. 2012;487(7408):505–509.
- Montagut C, Sharma SV, Shioda T, et al. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res. 2008;68(12):4853–4861.
- Johannessen CM, Boehm JS, Kim SY, et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature. 2010;468(7326):968–972.
- Wagle N, Emery C, Berger MF, et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol. 2011;29(22):3085–3096.
- Wang H, Daouti S, Li WH, et al. Identification of the MEK1(F129L) activating mutation as a potential mechanism of acquired resistance to MEK inhibition in human cancers carrying the B-RafV600E mutation. Cancer Res. 2011;71(16):5535–5545.
- Villanueva J, Vultur A, Lee JT, et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell. 2010;18(6):683–695.
- Nathanson KL, Martin AM, Wubbenhorst B, et al. Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436). Clin Cancer Res. 2013;19(17):4868–4878.
- Straussman R, Morikawa T, Shee K, et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature. 2012;487(7408):500–504.
- Fedorenko IV, Abel EV, Koomen JM, et al. Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells. Oncogene. 2016;35(10):1225–1235.
- Fedorenko IV, Wargo JA, Flaherty KT, et al. BRAF inhibition generates a host-tumor niche that mediates therapeutic escape. J Invest Dermatol. 2015;135(12):3115–3124.
- Hirata E, Girotti MR, Viros A, et al. Intravital imaging reveals how BRAF inhibition generates drug-tolerant microenvironments with high integrin β1/FAK signaling. Cancer Cell. 2015;27(4):574–588.
- Ravindran Menon D, Das S, Krepler C, et al. A stress-induced early innate response causes multidrug tolerance in melanoma. Oncogene. 2015;34(34):4448–4459.
- Genentech USA Inc. Cottellic (cobimetinib) tablets, for oral use: US prescribing information. 2015. [cited 2016 Mar 31]. Available from: http://www.gene.com/
- European Medicines Agency. Cotellic (cobimetinib): EU summary of product characteristics. 2015. [cited 2016 Mar 31]. Available from: http://www.ema.europa.eu/ema/
- Musib L, Choo E, Deng Y, et al. Absolute bioavailability and effect of formulation change, food, or elevated pH with rabeprazole on cobimetinib absorption in healthy subjects. Mol Pharm. 2013;10(11):4046–4054.
- Genentech USA Inc. ZELBORAF® (vemurafenib) tablet for oral use. [cited 2016 Mar 31]. Available from: http://www.gene.com/
- European Medicines Agency. Zelboraf (vemurafenib): EU summary of product characteristics. [cited 2016 Mar 31]. Available from: http://www.ema.europa.eu/ema/
- Ribas A, Zhang W, Chang I, et al. The effects of a high-fat meal on single-dose vemurafenib pharmacokinetics. J Clin Pharmacol. 2014;54(4):368–374.
- Han K, Jin JY, Marchand M, et al. Population pharmacokinetics and dosing implications for cobimetinib in patients with solid tumors. Cancer Chemother Pharmacol. 2015;76(5):917–924.
- Clinical Review, Giusti RM. NDA 206192, Cobimetinib in combination with Vemurafenib. [cited 2016 Mar 31]. Available from: http://www.accessdata.fda.gov/
- MEK4592g study/NCT00467779. [cited 2016 Mar 31]. Available from: https://clinicaltrials.gov/ct2/show/NCT00467779
- European Medicines Agency. Cotellic (cobimetinib): EPAR. 2015. [cited 2016 March 31]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/003960/WC500198565.pdf
- Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247
- Pavlick AC, Ribas A, Gonzalez R, et al. Extended follow-up results of phase Ib study (BRIM7) of vemurafenib (VEM) with cobimetinib (COBI) in BRAF-mutant melanoma. J Clin Oncol. 2015;33(15 Suppl).
- Larkin JMG, Yan Y, McArthur GA, et al. Update of progression-free survival (PFS) and correlative biomarker analysis from coBRIM: phase III study of cobimetinib (cobi) plus vemurafenib (vem) in advanced BRAF-mutated melanoma. J Clin Oncol. 2015;33(15 suppl).
- MEK4752g study/NCT00996892. [cited 2016 Mar 31]. Available from: https://clinicaltrials.gov/ct2/show/NCT00996892
- GE28079 study/NCT01562275. [cited 2016 Mar 31]. Available from: https://clinicaltrials.gov/ct2/show/NCT01562275
- GP28363 study/NCT01988896. [cited 2016 Mar 31]. Available from: https://clinicaltrials.gov/ct2/show/NCT01988896
- Ribas A, Hodi FS, Callahan M, et al. Hepatotoxicity with combination of vemurafenib and ipilimumab. New England J Med. 2013;368(14):1365–1366.
- Ribas A, Hodi F, Kurland J, et al. CA184-161: A phase I/II trial of vemurafenib and ipilimumab in patients with BRAF V600 mutation-positive metastatic melanoma. J Clin Oncol. 2012;30:suppl; abstr TPS8603.
- Hassel JC, Lee SB, Meiss F, et al. Vemurafenib and ipilimumab: a promising combination? Results of a case series. OncoImmunology. 2016;5(4):e1101207.
- Ribas A, Butler M, Lutzky J, et al. Phase I study combining anti-PD-L1 (MEDI4736) with BRAF (dabrafenib) and/or MEK (trametinib) inhibitors in advanced melanoma. J Clin Oncol. 2015;33(15 suppl).
- NEO-VC/NCT02303951. [cited 2016 Mar 31]. Available from: https://clinicaltrials.gov/ct2/show/NCT02303951
- Das Thakur M, Stuart DD. The evolution of melanoma resistance reveals therapeutic opportunities. Cancer Res. 2013;73(20):6106–6110.
- Long GV, Fung C, Menzies AM, et al. Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma. Nat Commun. 2014;5:5694 doi:10.1038/ncomms6694.
- NCT02583516 trial. [cited 2016 Mar 31]. Available from: https://clinicaltrials.gov/ct2/show/NCT02583516
- Long GV, Trefzer U, Davies MA, et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(11):1087–1095.
- Dummer R, Goldinger SM, Turtschi CP, et al. Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study. Eur J Cancer. 2014;50(3):611–621.
- coBRIM-B/NCT02230306. [cited 2016 Mar 31]. Available from: https://clinicaltrials.gov/ct2/show/NCT02230306
- Yee MK, Lin Y, Gorantla VC, et al. Phase 2 study of cobimetinib in combination with vemurafenib in active melanoma brain metastases (coBRIM-B). J Clin Oncol. 2015;33(15 suppl).
- Su F, Viros A, Milagre C, et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med. 2012;366(3):207–215.
- Gibney GT, Messina JL, Fedorenko IV, et al. Paradoxical oncogenesis—the long-term effects of BRAF inhibition in melanoma. Nat Rev Clin Oncol. 2013;10(7):390–399.
- Anforth R, Carlos G, Clements A, et al. Cutaneous adverse events in patients treated with BRAF inhibitor-based therapies for metastatic melanoma for longer than 52 weeks. Br J Dermatol. 2015;172(1):239–243.
- Grob JJ, Amonkar MM, Karaszewska B, et al. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. Lancet Oncol. 2015;16(13):1389–1398.
- Dréno B, Bartley K, Ascierto P, et al. Quality-of-life (QOL) assessment in patients (pts) with metastatic melanoma receiving vemurafenib (V) and cobimetinib (C). J Clin Oncol. 2015;33(15 suppl).
- Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012;367(2):107–114.
- MEKINIST (trametinib) tablets, for oral use. [cited 2016 Mar 31]. Availabel from: http://www.accessdata.fda.gov/
- European Medicines Agency. Mekinist (trametinib): EU summary of product characteristics. [cited 2016 Mar 31]. Available from: http://www.ema.europa.eu/ema/
- Sullivan R, Weber J, Patel S, et al. A phase Ib/II study of BRAF inhibitor (BRAFi) encorafenib (ENCO) plus MEK inhibitor (MEKi) binimetinib (BINI) in cutaneous melanoma patients naive to BRAFi treatment. J Clin Oncol. 2015;33(15 suppl).
- COLUMBUS trial/NCT01909453. [cited 2016 Mar 31]. Available from: https://clinicaltrials.gov/ct2/show/NCT01909453
- Smith MP, Brunton H, Rowling EJ, et al. Inhibiting drivers of non-mutational drug tolerance is a salvage strategy for targeted melanoma therapy. Cancer Cell. 2016;29(3):270–284.
- Krayem M, Journe F, Wiedig M, et al. p53 Reactivation by PRIMA-1(Met) (APR-246) sensitises (V600E/K)BRAF melanoma to vemurafenib. Eur J Cancer. 2016;55:98–110.
- Penna I, Molla A, Grazia G, et al. Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade. Oncotarget. 2016;7(4):3947–3965.
- Krepler C, Xiao M, Sproesser K, et al. Personalized preclinical trials in BRAF inhibitor-resistant patient-derived xenograft models identify second-line combination therapies. Clin Cancer Res. 2016;22(7):1592–1602.
- Atiq R, Hertz R, Eldad S, et al. Suppression of B-Raf(V600E) cancers by MAPK hyper-activation. Oncotarget. 2016;7(14):18694–18704.
- NCT01902173 trial. [cited 2016 Mar 31]. Available from: https://clinicaltrials.gov/ct2/show/NCT01902173
- NCT02110355 trial. [cited 2016 Mar 31]. Available from: https://clinicaltrials.gov/ct2/show/NCT02110355